MoneyWorks4Me

NGL Fine-Chem - Quaterly Results

21 May 2024 Evaluate
The sales for the March 2024 quarter moved up 31.08% to Rs. 956.09 millions as compared to Rs. 729.42 millions during the corresponding quarter last year.A good growth in profit of 27.21% reported to Rs. 108.50  millions over Rs. 85.29 millions of corresponding previous quarter.Operating profit surged to 167.60 millions from the corresponding previous quarter of 133.21 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 956.09 729.42 31.08 3289.73 2750.52 19.60 3289.73 2750.52 19.60
Other Income 41.64 26.86 55.03 159.01 76.12 108.89 159.01 76.12 108.89
PBIDT 167.60 133.21 25.82 601.94 356.96 68.63 601.94 356.96 68.63
Interest 4.58 3.22 42.24 13.38 11.97 11.78 13.38 11.97 11.78
PBDT 163.02 129.99 25.41 588.56 344.99 70.60 588.56 344.99 70.60
Depreciation 20.64 19.17 7.67 81.48 78.99 3.15 81.48 78.99 3.15
PBT 142.38 110.82 28.48 507.08 266.00 90.63 507.08 266.00 90.63
TAX 33.88 25.53 32.71 121.89 64.81 88.07 121.89 64.81 88.07
Deferred Tax 1.13 -3.97 -128.46 7.76 -7.30 -206.30 7.76 -7.30 -206.30
PAT 108.50 85.29 27.21 385.19 201.19 91.46 385.19 201.19 91.46
Equity 30.89 30.89 0.00 30.89 30.89 0.00 30.89 30.89 0.00
PBIDTM(%) 17.53 18.26 -4.01 18.30 12.98 40.99 18.30 12.98 40.99
Peers
Company Name CMP
Sun Pharma. Inds. 1853.00
Dr. Reddys Labs. 1200.40
Cipla 1404.00
Lupin 2098.00
Zydus Lifesciences 1180.00
View more..